TTBK2 Antibody | 5021

TTBK2 Antibody | 5021 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: Predicted species reactivity based on immunogen sequence: Mouse: (88%)

Immunogen: TTBK2 antibody was raised against an 18 amino acid synthetic peptide near the carboxy terminus of human TTBK2.
The immunogen is located within the last 50 amino acids of TTBK2.

Research Area: Neuroscience

Tested Application: E, IHC-P

Application: TTBK2 antibody can be used for detection of TTBK2 by immunohistochemistry at 5 μg/mL.
Antibody validated: Immunohistochemistry in human samples. All other applications and species not yet tested.

Specificiy: TTBK2 antibody is human specific. At least four isoforms of TTBK2 are known to exist; this antibody will detect only the two largest isoforms.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: TTBK2 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: TTBK2 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: TTBK2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: TTBK2 Antibody: TTBK, SCA11, KIAA0847, Tau-tubulin kinase 2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: TTBK2 Antibody: Tau tubulin kinase (TTBK2) is a serine/threonine kinase whose substrates are thought to include the tau and tubulin proteins. Mutations in the TTBK2 gene cause spinocerebellar ataxia type 11 (SCA11) , a neurodegenerative disease characterized by progressive ataxia and atrophy of the cerebellum and brainstem. Recent studies have shown that increased levels of TTBK2 expression in kidney carcinoma and melanoma cell lines increases resistance to the chemotherapeutic agent Sunitinib, and that reduction of TTBK2 though the use of siRNA sensitized these cell lines to the effects of Sunitib, suggesting that TTBK2 can be used as a resistance marker as well a potential target to overcome resistance.